ClinicalTrials.gg
RecruitingNCT07165886Updated Apr 24, 2026

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

A Phase 2/3 interventional study of Sirolimus for injection (albumin bound) and Octreotide long-acting injection in Gastroenteropancreatic Neuroendocrine Tumors, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
298
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

There is limited evidence regarding the benefit of adding somatostatin analogs to molecular targeted agents for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with poor prognostic factors. This trial is conducted to evaluate sirolimus for injection (albumin bound) combined with octreotide long-acting injection in patients with unresectable or recurrent GEP-NETs.

02

Conditions studied

  • Gastroenteropancreatic Neuroendocrine Tumors
03

In context

Gastro-enteropancreatic neuroendocrine tumor

73 studies on the registry are indexed under Gastro-enteropancreatic neuroendocrine tumor; 25 are open to participants now.

This study's planned enrollment of 298 is above the median of 53 across 49 interventional studies indexed under Gastro-enteropancreatic neuroendocrine tumor.

Browse Gastro-enteropancreatic neuroendocrine tumor studies →

Lead sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Unresectable locally advanced or G1/G2 GEP-NETs diagnosed by histology, according to the 2019 WHO histological grading criteria.
  • 2. Having poor prognostic factors.
  • 3. Non-functional GEP-NETs are required.
  • 4. At least one evaluable lesion meets the V1.1 standard (Applicable only to the phase II safety run-in stage)
  • 6. 0\~2.
  • 7. Organ function reserve is good.
  • 8. Be able to sign a written form.

Exclusion criteria

Exclusion Criteria:

  • 1. Patients who have previously received SSTR-targeted therapies (including somatostatin analogs [SSAs] and peptide receptor radionuclide therapy) and/or mTOR inhibitors (Patients who received SSAs in the setting and experienced recurrence ≥6 months after treatment completion may be enrolled)[ Applicable to Phase II dose expansion and Phase III stages].
  • 2. Has uncontrolled/severe diarrhea or an axillary temperature > 38.0°C at enrollment.
  • 3. Received treatment with other unlisted clinical drugs within 4 weeks prior to the first use of the investigational drug.
  • 4. Undergone major surgical procedures within 4 weeks prior to the first use of the investigational drug and have not fully recovered.
  • 5. Received systemic use of or other therapy within 2 weeks prior to the first use of the study drug.
  • 6. With an infection that requires systemic anti-infective treatment within 2 weeks prior to the first use of the study drug.
  • 7. Those who have used strong inhibitors or inducers of liver metabolic enzymes within 2 weeks prior to the first use of the investigational drug or still need to continue using such drugs.
  • 8. Has a serious history of cardiovascular and cerebrovascular diseases.
  • 9. Having active and/or malignant meningitis.
  • 10. With a history of severe lung diseases.
  • 11. During screening, there may be symptomatic gallstones or a history of symptomatic gallstones but no surgical treatment has been performed.
  • 12. Abnormal thyroid function during screening.
  • 13. Known to have reactions or intolerance to any component of all investigational drugs or their .
  • 14. Active , active virus infection, or active syphilis infection.
  • 15. History of diseases (excluding tuberous sclerosis), history of immunodeficiency, including testing positive, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
298 participants (estimated)

Study arms

  • Experimental
    Sirolimus combined with octreotide

    Sirolimus for injection (albumin bound) combined with octreotide long-acting injection will be administrated on a 28-day cycle

    Drug: Sirolimus for injection (albumin bound) · Drug: Octreotide long-acting injection

  • Experimental
    Sirolimus monotherapy

    Sirolimus for injection (albumin bound) will be administrated on a 28-day cycle.

    Drug: Sirolimus for injection (albumin bound)

  • Active comparator
    Everolimus monotherapy

    Everolimus (QD) will be orally administrated on a 28-day cycle. Only for Phase III

    Drug: Everolimus

Interventions

06

What researchers measure

Primary outcomes

  1. Phase II: Incidences of Adeverse Events (AEs)

    Time frame: Up to 3 years

  2. Phase II: Dose Limiting Toxicity (DLT)

    Time frame: Up to 1 year

  3. Phase II: Recommended Phase 3 Dose (RP3D)

    Time frame: Up to 1 year

  4. Phase II: Objective Response Rate (ORR) per investigator

    Time frame: Up to 1 year

  5. Phase III: Progression Free Survival (PFS) per Blinded Independent Review Committee (BIRC)

    Time frame: Up to 3 years

Secondary outcomes

  1. Phase II: Duration of Response (DOR) per investigator

    Time frame: Up to 3 years

  2. Phase II: Disease Control Rate (DCR) per investigator

    Time frame: Up to 3 years

  3. Phase II: Progression Free Survival (PFS) per investigator

    Time frame: Up to 3 years

  4. Phase II: Overall Survival (OS)

    Time frame: Up to 3 years

  5. Peak Concentration:Cmax

    Time frame: Up to 3 years

  6. Area under the plasma concentration-time curve: AUC

    Time frame: Up to 3 years

  7. Half-Life: t1/2

    Time frame: Up to 3 years

  8. Phase II: Blood concentrations and PK parameters of sirolimus for injection(albumin bound) and Octreotide long-acting injection.

    Time frame: From first dose of treatment to C3D15

  9. Phase II: Changes in serum chromogranin A, 24-hour urinary 5-hydroxyindoleacetic acid, and serum IGF-1 levels from baseline.

    Time frame: From first dose of treatment to end of treatment

  10. Phase III: Progression Free Survival (PFS) per investigator

    Time frame: Up to 3 years

  11. Phase III: Objective Response Rate (ORR)

    Time frame: Up to 3 years

  12. Phase III: Duration of Response (DOR)

    Time frame: Up to 3 years

  13. Phase III: Disease Control Rate (DCR)

    Time frame: Up to 3 years

  14. Phase III: Incidences of Adeverse Events (AEs)

    Time frame: Up to 3 years

  15. Phase III: Overall Survival (OS)

    Time frame: Up to 3 years

  16. Phase III: Changes in serum chromogranin A, 24-hour urinary 5-hydroxyindoleacetic acid, and serum IGF-1 levels from baseline.

    Time frame: From first dose of treatment to end of treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Aug 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 10, 2025
StartActual
Aug 29, 2025
Primary completionEst.
Aug 29, 2028
CompletionEst.
Aug 29, 2028
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07165886
Responsible party
Sponsor
First posted
Sep 10, 2025
Start date
Aug 29, 2025
Primary completion
Aug 29, 2028 (estimated)
Completion
Aug 29, 2028 (estimated)
Last update
Apr 24, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion